SynthesisCells2021
Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.
Synthesis in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07604467 (Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- CD34Histology and histopathology · 2026Review
- Review
- The Inhibition of Prolyl Endopeptidase (PREP) by KYP-2047 Treatment to Reduce Myocardial Ischemia/Reperfusion Injury.Antioxidants (Basel, Switzerland) · 2025Article
- Anti-inflammatory Prowess of endothelial progenitor cells in the realm of biology and medicine.NPJ Regenerative medicine · 2024Review
- Novel diagnostic approaches and management of coronary microvascular dysfunction.American journal of preventive cardiology · 2024Article
- INOCA/ANOCA: Mechanisms and novel treatments.American heart journal plus : cardiology research and practice · 2023Article
- Cells and Materials for Cardiac Repair and Regeneration.Journal of clinical medicine · 2023Review
- Global trend and future landscape of coronary microcirculation: A bibliometric and visualized analysis from 1990 to 2021.Heliyon · 2023Article
- Ischemia and no obstructive coronary arteries (INOCA): A narrative review.Atherosclerosis · 2022Review
- Review
- CD34Cellular and molecular life sciences : CMLS · 2022Article
- Myocardial regeneration protocols towards the routine clinical scenario: An unseemly path from bench to bedside.EClinicalMedicine · 2022Review
- Contemporary Management of Refractory Angina.Interventional cardiology clinics · 2022Review
- Stem Cell Therapy Targets: Repêchage!Circulation research · 2022Article
- Stem Cells to the Rescue: Development and Application of Cell-Based Therapy for Microvascular Repair.Cells · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Ischemia with non-obstructive coronary arteries (INOCA) is an increasingly recognized disease, with a prevalence of 3 to 4 million individuals, and is associated with a higher risk of morbidity, mortality, and a worse quality of life. Persistent angina in many patients with INOCA is due to coronary microvascular dysfunction (CMD), which can be difficult to diagnose and treat. A coronary flow reserve <2.5 is used to diagnose endothelial-independent CMD. Antianginal treatments are often ineffective in endothelial-independent CMD and thus novel treatment modalities are currently being studied for safety and efficacy. CD34
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.